



HHS Public Access

Author manuscript

Mol Microbiol. Author manuscript; available in PMC 2022 September 01.

Published in final edited form as:

Mol Microbiol. 2021 September ; 116(3): 877–889. doi:10.1111/mmi.14777.

CroS_{R391}, an ortholog of the λ Cro repressor, plays a major role in suppressing polV_{R391}-dependent mutagenesis

John P. McDonald¹, Dominic R. Quiros¹, Alexandra Vaisman¹, Antonio R. Mendez², Jan Reyelt^{3,†}, Marlen Schmidt³, Martín Gonzalez^{2,*}, Roger Woodgate^{1,*}

¹Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-3371, USA

²Department of Biology, Southwestern University, Georgetown, TX 78626, USA

³Gen-H Genetic Engineering Heidelberg GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg, Germany

Abstract

When subcloned into low-copy-number expression vectors, *rumAB*, encoding polV_{R391} (RumA_{2B}), is best characterized as a potent mutator giving rise to high levels of spontaneous mutagenesis *in vivo*. This is in dramatic contrast to the poorly mutable phenotype when polV_{R391} is expressed from the native 88.5kb R391, suggesting that R391 expresses *cis*-acting factors that suppress the expression and/or the activity of polV_{R391}. Indeed, we recently discovered that SetR_{R391}, an ortholog of λ cI repressor, is a transcriptional repressor of *rumAB*. Here, we report that CroS_{R391} an ortholog of λ Cro, also serves as a potent transcriptional repressor of *rumAB*. Levels of RumA are dependent upon an interplay between SetR_{R391} and CroS_{R391}, with the greatest reduction of RumA protein levels observed in the absence of SetR_{R391} and presence of CroS_{R391}. Under these conditions, CroS_{R391} completely abolishes the high levels of mutagenesis promoted by polV_{R391} expressed from low-copy-number plasmids. Furthermore, deletion of *croS_{R391}* on the native R391 results in a dramatic increase in mutagenesis, indicating that CroS_{R391} plays a major role in suppressing polV_{R391} mutagenesis *in vivo*. Inactivating mutations in CroS_{R391} therefore have the distinct possibility of increasing cellular mutagenesis that could lead to the evolution of antibiotic resistance of pathogenic bacteria harboring R391.

Abbreviated Summary

*Correspondence: Roger Woodgate, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-3371, USA, woodgate@nih.gov, Tel: 301-435-4040, Martín Gonzalez, Department of Biology, Southwestern University, Georgetown, TX 78626, USA, gonzale2@southwestern.edu, Tel: 512-863-1621.

†Present Address: AGC Biologics GmbH, Czernyring 22, 69115 Heidelberg, Germany

AUTHOR CONTRIBUTIONS

Conceptualization: JPM, MG, RW

Funding Acquisition: MG, RW

Investigation: JPM, DRQ, AV, ARM, JR, MS, MG, RW

Writing-Original Draft: JPM, RW

Writing-Review and Editing: JPM, DRQ, AV, ARM, JR, MS, MG, RW


CONFLICT OF INTEREST

The authors declare that they have no conflict of interest with the content of this article.

†Formerly Service Unit of Gene Bridges GmbH

When subcloned from R391 into low-copy-number expression vectors, $\text{polV}_{\text{R391}}$ (RumA'2B) encoded by *rumAB*, is a potent mutator giving rise to high levels of spontaneous mutagenesis *in vivo*. This is in contrast to the poorly mutable phenotype when $\text{polV}_{\text{R391}}$ is expressed from the native R391. Here, we report that $\text{CroS}_{\text{R391}}$ an ortholog of λCro , serves as a potent transcriptional repressor of *rumAB* that plays a major role in suppressing $\text{polV}_{\text{R391}}$ mutagenesis *in vivo*.

Graphical Abstract



Keywords

SOS response; Integrating Conjugative Element; Mutagenesis; DNA polymerase V; R391

1 | INTRODUCTION

The accelerating emergence of drug resistant pathogenic micro-organisms is a critical global public health concern (<https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>). Antibiotic over-use and prophylaxis, in both humans and livestock, for the treatment of disease-causing bacteria has led to the selection and increased prevalence of so-called “super-bugs” that have often acquired resistance to multiple classes of antimicrobial compounds (Wendlandt *et al.*, 2015). Estimates suggest a ten-fold increase in mortality rates from untreatable bacterial infections within the next 30 years (https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf). The urgency of this impending crisis has recently led to a concerted effort to identify new synthetic compounds and natural products that might represent novel families

of antibiotics (Bhattarai *et al.*, 2020). In addition, the genetic mechanisms that give rise to antibiotic resistance, such as stress-induced mutagenesis and broad-host-range drug-resistance genetic elements (i.e., plasmids, genomic islands and integrative and conjugative elements [ICE]) are being extensively studied as potential targets for mitigating the development of resistance.

E. coli possesses five DNA polymerases, three of which, pol II (encoded by *polB*), pol IV (encoded by *dinB*) and polV (encoded by *umuDC*) are induced as part of the SOS response to stress and DNA damage (Simmons *et al.*, 2008). Expression of these polymerases has previously been shown to contribute to the evolution of antibiotic drug resistance in many pathogenic strains of bacteria (Cirz *et al.*, 2006a; Cirz *et al.*, 2006b; Cirz & Romesberg, 2006; Cirz *et al.*, 2007). PolV alone is responsible for up to a hundred-fold increase in spontaneous mutagenesis after SOS-induction (Sweasy *et al.*, 1990; Fijalkowska *et al.*, 1997). As a consequence, the activity of polV is subject to multiple levels of regulation (Goodman *et al.*, 2016). In addition to transcriptional repression by the SOS repressor, LexA (Bagg *et al.*, 1981), the UmuD protein has to undergo activated RecA (RecA*)-mediated posttranslational cleavage to UmuD' (Burckhardt *et al.*, 1988; Nohmi *et al.*, 1988; Shinagawa *et al.*, 1988), so that it can interact with UmuC (Woodgate *et al.*, 1989) and generate polV (UmuD'₂C) (Tang *et al.*, 1999). Cleavage of UmuD to UmuD' also leads to a change in the spatial location of polV inside the cell (Robinson *et al.*, 2015). polVs activity is further increased through an interaction with RecA and ATP to generate the polV Mutasome (polV Mut) (Jiang *et al.*, 2009). Last, but not least, intracellular levels of UmuD, UmuD' and UmuC are normally kept to a minimum through targeted proteolysis (Frank *et al.*, 1996; Gonzalez *et al.*, 1998; Gonzalez *et al.*, 2000).

polV orthologs are found in many strains of bacteria, as well as bacteriophage, self-transmissible R-plasmids, and integrating conjugative elements (ICEs) (Pinney, 1980; Upton & Pinney, 1983; Ho *et al.*, 1993; McLenigan *et al.*, 1999). Given that these orthologs are located on mobile genetic elements and are likely to find themselves in very different genetic environments, one might expect alternate mechanisms of regulation to keep their activity in check until needed.

A good example is the LexA-regulated polV ortholog (encoded by *rumAB*) found on R391. R391 and a closely related ICE, SXT, exhibit 95% identity over 65 kb of their sequences (Hochhut *et al.*, 2001). However, one notable difference between R391 and SXT is that *rumB* is inactivated in SXT due to the insertion of an *ISCR2* element into the gene and as a consequence, in contrast to R391, SXT does not possess an active polV.

SetR_{SXT} a λ cI-like repressor, has been shown to regulate genes involved in conjugation, integration and excision of the SXT element (Beaber *et al.*, 2004; Poulin-Laprade & Burrus, 2015; Poulin-Laprade *et al.*, 2015). Previously, we examined the role of the related SetR_{R391} protein for its role in regulating polV_{R391} (Gonzalez *et al.*, 2019). We found that the regulatory region of the *rumAB*_{R391} operon contains a single site that is highly similar to the known multiple SetR_{SXT} 14 bp operator sequences (Figure 1), leading us to suggest that SetR_{R391} could be involved in the repression of the *rumAB*_{R391} genes. We found that co-expression of *rumAB*_{R391} and *setR*_{R391} from the same low-copy plasmid reduced

the levels of mutagenesis observed in a *lexA* defective SOS-induced strain indicating that SetR_{R391} can regulate the *rumAB*_{R391} genes (Gonzalez et al., 2019). Moreover, SetR_{R391} protein was shown to specifically bind to the 14 bp operator sequence that overlaps with the -35 promoter element upstream of *rumAB* (Figure 1). However, we found that plasmid pRLH421, which contains ~ 21.5 kb of R391, including both *setR*_{R391} and *rumAB*, nevertheless exhibited very high levels of mutagenesis in an SOS-induced strain [*recA718 lexA51(Def)*]. We argued that, in this SOS-induced strain, the activated RecA co-protease (encoded by *recA718*) cleaves the SetR_{R391} protein, in a similar fashion to LexA cleavage, inactivating SetR_{R391} and allowing expression of the *rumAB* operon. Indeed, when a non-cleavable allele of *setR*_{R391} was cloned into pRLH421, we observed a significant decrease in mutagenesis (Gonzalez et al., 2019). Additional experiments revealed, however, that intact R391 exhibits even lower levels of mutagenesis in strains in which RecA is in a constitutively and highly activated state (*recA730*), suggesting that there is at least one additional negative regulator of the *rumAB*_{R391} genes encoded by R391 that is not affected by activated RecA (unpublished observations).

R391 also expresses a protein that is phylogenetically related to Cro-like transcriptional repressor proteins (Figure S1) (Boltner *et al.*, 2002). While the CroS_{R391} protein shows some phylogenetic divergence from related Cro-like proteins, it is 100% identical to the CroS_{SXT} protein (Figure S1). Previous studies on the CroS_{SXT} and SetR_{SXT} proteins revealed that they both bind to four conserved operator sequences; *OL*, *O1*, *O2* and *O3* (albeit with differing affinities) in the *croS-setR* intergenic region which regulates their own expression from divergent promoters (Poulin-Laprade & Burrus, 2015). In SXT, it is known that CroS_{SXT} also regulates the *setCD*_{SXT} genes and, similar to SetR_{SXT}, is involved in regulating conjugative transfer (Poulin-Laprade & Burrus, 2015; Poulin-Laprade *et al.*, 2015). The interplay between the ICE SetR_{SXT} and CroS_{SXT} proteins is therefore reminiscent of the λ cI and λ Cro proteins that govern the transition between lysogenic and lytic pathways during the bacteriophage life cycle (Takeda *et al.*, 1977; Johnson *et al.*, 1978; Svenningsen *et al.*, 2005).

We hypothesized that like SetR_{R391}, CroS_{R391} would function as a transcriptional regulator of the *rumAB*_{R391} operon and thereby play a role in regulating *rumAB*_{R391}-mediated mutagenesis. To test this hypothesis, we have constructed a series of plasmids expressing SetR_{R391} and/or CroS_{R391} and investigated their effects on *rumAB* expression and polV_{R391}-dependent mutagenesis *in vivo*. We report here, that CroS_{R391} is a transcriptional repressor of *rumAB* and may be the major factor that suppresses polV_{R391} activity on R391.

2 | RESULTS

2.1 | Comparison of polV_{R391}-dependent mutagenesis when *rumAB* is expressed from R391, or sub-cloned onto a low-copy-number vector.

Our studies examined the multifaceted nature of the regulation of the R391 mutagenic response. Regulation of the mutagenic activity of polV_{R391} when expressed in its native genetic environment promotes minimal levels of mutagenesis (Pinney, 1980), even in strains in which the LexA repressor is inactivated and RecA is constitutively activated (previous unpublished observations and Figure 2). However, when *rumAB* was subcloned onto a low-

copy-number plasmid, there was a dramatic increase in $\text{polV}_{\text{R391}}$ mutator activity, especially in strains with mutations in *recA* (*recA718* and *recA730*) that lead to a constitutive RecA^* phenotype (Ho et al., 1993) (Figure 2). Indeed, $\text{polV}_{\text{R391}}$ is the most potent polV ortholog characterized to date (Kulaeva et al., 1995; Mead et al., 2007). The fact that $\text{polV}_{\text{R391}}$ appears inactive when expressed from the native R391 indicates that there is likely to be *cis*-acting factor(s) expressed from R391 that normally act to suppress the potent mutator activity of $\text{polV}_{\text{R391}}$.

2.2 | $\text{CroS}_{\text{R391}}$ plays a major role in suppressing $\text{polV}_{\text{R391}}$ -dependent mutagenesis.

The *rumAB* operon was originally subcloned in 1993 into the low-copy vector pGB2 (Churchward et al., 1984) as a partial *EcoRI* digest of R391 (Ho et al., 1993). R391 is normally chromosomally located and integrated into the 5' end of *prfC* (Hochhut et al., 2001). However, the 21.5 kb insert cloned into pGB2 to generate pRLH421 is clearly of episomal origin, since it contains both 5' and 3' ends of the linear R391. Unfortunately, sequence analysis of the insert in pRLH421 (Genbank: U13633) reveals that the $\text{croS}_{\text{R391}}$ gene is truncated at an internal *EcoRI* site in the gene (Figure S2). We suspected that the croS_- C truncation could explain our disparate mutagenesis results with pRLH421 (high levels), versus intact R391 (low levels), if $\text{CroS}_{\text{R391}}$ does indeed repress the $\text{rumAB}_{\text{R391}}$ genes. To test this notion, we constructed a series of pRLH421-derived plasmids with combinations of wild-type $\text{croS}_{\text{R391}}$ and $\text{setR}_{\text{R391}}$, and/or deletions of $\text{croS}_{\text{R391}}$ and $\text{setR}_{\text{R391}}$ while still retaining the *rumAB* operon (Table 1) (Figure S2).

The various plasmid iterations of $\text{croS}_{\text{R391}}$ and $\text{setR}_{\text{R391}}$ were transformed into MVG114 [*umuDC596::ermGT*, *lexA51(Def)*, *recA718*, *hisG4(Oc)*] in order to analyze RumAB -dependent spontaneous mutagenesis utilizing the histidine reversion assay. In the *lexA51(Def)* background, the RecA718 protein is in a partially activated state (RecA^*) (McCall et al., 1987) and promotes significant levels of polV -dependent spontaneous mutagenesis in the absence of DNA damage (Sweasy et al., 1990). As with our earlier findings (Ho et al., 1993), pRLH421 gave very high levels of mutagenesis (Figure 3). Similarly, both the $\text{croS}_{\text{R391}} / \text{setR}^+_{\text{R391}}$ construct (pJM1355) and the double $\text{croS}_{\text{R391}} / \text{setR}_{\text{R391}}$ construct (pJM1359) also gave high levels of mutagenesis revealing that the *rumAB* operon is not appreciably down-regulated in the *recA718 lexA51(Def)* background. However, in strains harboring plasmid constructs that express $\text{croS}_{\text{R391}}$ the level of mutagenesis is significantly reduced. While the levels of mutagenesis with the $\text{croS}^+_{\text{R391}} / \text{setR}^+_{\text{R391}}$ construct (pJM1356) are reduced 2.7-fold (c.f. pJM1355) to 4.2-fold (c.f. pRLH421), the $\text{croS}^+_{\text{R391}} / \text{setR}_{\text{R391}}$ construct (pJM1360) results in a 50- to 75-fold reduction in mutagenesis (Figure 3).

2.3 | $\text{CroS}_{\text{R391}}$ repression can operate *in trans* and is specific for the *rumAB* promoter.

To demonstrate that the regulation of *rumAB*-dependent mutagenesis was specifically due to $\text{CroS}_{\text{R391}}$ and not some other factor encoded in the R391 DNA cloned in the pRLH421 derivatives described above, we deleted ~ 20.3 kb from *ScaI* to *SmaI* of the R391 DNA leaving only the various $\text{croS}_{\text{R391}}$ and $\text{setR}_{\text{R391}}$ operons (Figure S2). pJM1378 (Table 1), a pCC1-derivative (Epicenter/Genscript), carrying the $\text{rumAB}_{\text{R391}}$ operon, including the *rumAB* promoter, was transformed alone, or in combination, with either

pJM1365 ($croS_{R391} / setR^+_{R391}$), pJM1366 ($croS^+_{R391} / setR^+_{R391}$), pJM1367 ($croS_{R391} / setR_{R391}$) and pJM1368 ($croS^+_{R391} / setR_{R391}$) into MVG114 [*umuDC596::ermGT*, *lexA51(Def)*, *recA718*, *hisG4(Oc)*]. Again, utilizing the histidine reversion mutagenesis assay, we found that *rumAB*-dependent mutagenesis was lower when expressing both wild-type $CroS_{R391}$ and $SetR_{R391}$ (pJM1366) corresponding to our above finding with plasmid pJM1356 ($croS^+_{R391} / setR^+_{R391}$) (Figure 4A & Figure S3). In contrast, when $setR_{R391}$ is deleted such that only $CroS_{R391}$ is expressed (pJM1368), *rumAB*-dependent mutagenesis is virtually eliminated (Figure 4A & Figure S3), again in agreement with the results with pJM1360 ($croS^+_{R391} / setR_{R391}$). Furthermore, we found that in all strains where there is no $CroS_{R391}$ expressed (pJM1378 alone, or with pJM1365, or pJM1367), there is a very high level of spontaneous mutagenesis. These results confirm that regulation of *rumAB*-dependent mutagenesis occurs during an interplay between $SetR_{R391}$ and $CroS_{R391}$ and that this regulation can operate in *trans*.

Knowing that there is a single $SetR_{R391}$ binding site upstream of the *rumAB*_{R391} operon (Figure 1) (Gonzalez et al., 2019) and that the four $SetR$ binding sites in the *setR-croS* intergenic region of the SXT element are also bound by $CroS_{SXT}$ (Poulin-Laprade & Burrus, 2015), we wanted to show that the $CroS_{R391}$ repression of *rumAB*_{R391} was dependent on the *rumAB* promoter region. We therefore replaced the *rumAB*_{R391} promoter region in pJM1378 with the promoter region of the *E. coli recA* gene, to create plasmid pJM1467 (*recA-promoter::rumAB*_{R391}) (Table 1). As before, pJM1467 was transformed alone, or in combination, with either pJM1365 ($croS_{R391} / setR^+_{R391}$), pJM1366 ($croS^+_{R391} / setR^+_{R391}$), pJM1367 ($croS_{R391} / setR_{R391}$) and pJM1368 ($croS^+_{R391} / setR_{R391}$) into MVG114 and histidine reversion mutagenesis was performed (Figure 5A & Figure S3). Most plasmid combinations gave uniformly high levels of mutagenesis. The exception was pJM1467 together with pJM1368 ($croS^+_{R391} / setR_{R391}$) that gave ~85% of the level of mutagenesis observed with the other plasmid combinations. It should be emphasized that this is in dramatic contrast to when $RumAB_{R391}$ is expressed from the native $SetR/CroS$ binding site-containing *rumAB* promoter, where $CroS_{R391}$ expressed from pJM1368 eliminated virtually all $RumAB$ -dependent mutagenesis (c.f. Figs. 4A, 5A and S3).

2.4 | $CroS_{R391}$ regulation of $RumA_{R391}$ protein level is specific to the *rumAB*_{R391} promoter.

In order to demonstrate that the $CroS_{R391}$ protein regulates mutagenesis by repressing the *rumAB* genes, we performed western blot analysis using rabbit anti- $CroS_{R391}$ (this study) and anti- $RumA_{R391}$ antibodies. Whole cell protein extracts were made from MVG114 strains harboring pJM1378 (*rumAB*) alone, or in combination, with either pJM1365 ($croS_{R391} / setR^+_{R391}$), pJM1366 ($croS^+_{R391} / setR^+_{R391}$), pJM1367 ($croS_{R391} / setR_{R391}$) or pJM1368 ($croS^+_{R391} / setR_{R391}$). As expected, only the strains harboring the pJM1366 ($croS^+_{R391} / setR^+_{R391}$) and pJM1368 ($croS^+_{R391} / setR_{R391}$) constructs expressed any $CroS_{R391}$ protein (Figure 4B) and the level of $CroS$ was identical in the presence or absence of $SetR$, suggesting that the phenotypic differences observed with the two plasmids (Figure 4A) is dependent on the presence of the $SetR$ protein, and not the level of $CroS$ protein. When compared to strains lacking $CroS$, the levels of $RumA_{R391}/RumA'_{R391}$ proteins are significantly reduced in the strains harboring the

pJM1366 (*croS*⁺_{R391} / *setR*⁺_{R391}) and pJM1368 (*croS*⁺_{R391} / *setR*_{R391}) constructs (Figure 4C). Moreover, in the strain harboring pJM1368, which expresses only CroS_{R391}, the level of RumA_{R391} protein is less than in the strain harboring pJM1366, despite expressing the same amount of CroS (Figure 4B) and the RumA'_{R391} protein is close to the limits of detection (Figure 4C). These findings demonstrate that the CroS_{R391} protein does indeed regulate the expression of the RumA_{R391} protein and that its regulation can be modulated in the presence of SetR_{R391}. In addition, in the absence of the SetR_{R391} protein (pJM1368), CroS_{R391} protein may also have some inhibitory effect on RecA-mediated cleavage of RumA_{R391} to RumA'_{R391} (see below for more discussion).

Next, we wanted to show that the CroS_{R391} regulation of RumA protein expression is specific to the *rumAB* promoter region. Plasmid pJM1467 (*recA-prom::rumAB*_{R391}), which expresses RumAB_{R391} from the *E. coli recA* promoter, was co-transformed into MVG114 along with either pJM1365 (*croS*_{R391} / *setR*⁺_{R391}), pJM1366 (*croS*⁺_{R391} / *setR*⁺_{R391}), pJM1367 (*croS*_{R391} / *setR*_{R391}), or pJM1368 (*croS*⁺_{R391} / *setR*_{R391}). Western blot analysis using the anti-RumA antibodies was performed (Figure 5B). We found that the levels of RumA_{R391}/RumA'_{R391} proteins are enhanced when expressed from the *E. coli recA* promoter as compared to RumA_{R391}/RumA'_{R391} protein expressed from the native *rumAB*_{R391} promoter. However, unlike the previous results, the levels of RumA_{R391} protein expressed from the *recA* promoter are not affected by the presence of the CroS_{R391} protein (pJM1366 and pJM1368) indicating that CroS_{R391} transcriptional repression is specific to the *rumAB*_{R391} promoter. Again, in the absence of the SetR_{R391} protein (pJM1368), we observed a reduction in cleavage of RumA_{R391} to RumA'_{R391} (Figure 5). We believe that the reduction in RumA cleavage is due to an indirect inhibitory effect of CroS_{R391} on the spontaneous generation of RecA* in the *recA718* strain, since significantly more RumA cleavage was observed in the same *recA718* strain exposed to the DNA damaging agent, Mitomycin C, or in the highly proficient RecA*-forming *recA730* strain (-/+ Mitomycin C) (Figure S4).

2.5 | Expression of RumA/RumA' in a *recA*⁺ *lexA*⁺ strain expressing SetR +/- and CroS +/- after antibiotic-induced SOS induction

Based on the known interplay between CroS and SetR (Poulin-Laprade & Burrus, 2015; Poulin-Laprade et al., 2015), we hypothesized that *rumAB* would be the most repressed upon conditions that activate R391 transfer, namely at low SetR concentrations and high CroS levels, after damage- or stress-induced induction of the SOS response. We were therefore interested in assaying expression of RumA in a wild-type *recA*⁺ *lexA*⁺ strain (RW520) harboring the various *setR-croS* plasmids, that also encode the *rumAB*_{R391} operon, (pJM1355, pJM1356, pJM1359 and pJM1360) in which the SOS response was stress-induced by treatment with the antibiotic, Ciprofloxacin, for up to 3 hours (Figure 6). Ciprofloxacin-mediated induction of the SOS response was followed by western blot analysis of the LexA-regulated RecA and RumA proteins. With all plasmid combinations, a strong induction of RecA was observed after treatment with Ciprofloxacin, indicating that the chromosomally-encoded LexA repressor had been inactivated *in vivo* (Figure 6). The lack of any effect of the various *setR-croS* plasmids on RecA expression also indicates that *recA* is not negatively regulated by either SetR or CroS. In contrast, the timing of the

induction of RumA_{R391} was dependent upon the presence, or absence, of SetR, or CroS (Figure 6). For example, in strains harboring pJM1359 (*croS*_{R391} / *setR*_{R391}), where *rumA* is only regulated by LexA, there was a time dependent induction of RumA, which peaked around 1 hr after Ciprofloxacin treatment, followed by conversion of RumA to RumA' 2–3 hrs post treatment. By comparison, the peak of RumA induction in the presence of pJM1355 (*croS*_{R391} / *setR*⁺_{R391}), was around 2 hrs, suggesting that the presence of SetR delays RumA expression by an hour. However, there was no effect on the conversion of RumA to RumA' which nevertheless occurred 2–3 hrs post treatment. (Fig. 6). In contrast, no Ciprofloxacin-induced expression of RumA was observed in the presence of pJM1360 (*croS*⁺_{R391} / *setR*_{R391}), consistent with our earlier observations (Figure 4C). Interestingly, in the presence of pJM1356 (expressing both *croS*⁺_{R391} / *setR*⁺_{R391}), expression of RumA peaked at 1hr post Ciprofloxacin treatment, from that point on, RumA levels decrease and by 3 hrs, they are barely detectable. Such observations can readily be explained by the interplay and hierarchy of the three transcriptional repressors. We know that LexA is cleaved just a few minutes after DNA damage, so as to induce the 40+ protein SOS regulon (Fernández de Henestrosa *et al.*, 2000). In contrast, SetR, which we have previously shown to be cleaved much slower than LexA *in vitro* (Gonzalez *et al.*, 2019), would be expected to be cleaved and inactivated by RecA* *in vivo* around the 1–2 hr point, which would then allow CroS_{R391} sole access to the SetR/CroS binding site in the *rumAB* promoter, thereby effectively eliminating residual expression of the RumA protein. The fact that RumA is detected in the *croS*⁺_{R391} / *setR*⁺_{R391} strain, but not the *croS*⁺_{R391} / *setR*_{R391} strain, implies that SetR_{R391} normally competes with CroS_{R391} *in vivo* and to some degree blocks its access to the SetR-CroS binding site in the *rumAB* promoter. Such a scenario explains why polV_{R391}, encoded by the stably integrated R391 promotes such low levels of mutagenesis after DNA damage, or in constitutively activated RecA* strains, where both LexA and SetR repressors are inactivated and *rumAB* is repressed solely by CroS (Figure 2).

2.6 | Deletion of *croS*_{R391} on R391 leads to enhanced mutagenesis

Since R391 stably integrates into the *E. coli* chromosome at the 5' end of the *prfC* gene (Hochhut *et al.*, 2001), we were able to construct a *croS*_{R391} deletion mutant in the MVG114 genetic background and compare mutagenesis between the R391 and the R391 *croS* strains. First, we examined mutagenesis using a *galK2(Oc)* reversion papillation assay in which orange-red Gal⁺ mutant “papillae” grow up within bacterial colonies plated on MacConkey-galactose agar media. Representative colonies from the R391 and R391 *croS* strains are shown in Figure 7. The R391 strains gave 0 – 3 Gal⁺ mutant papillae per colony, whereas the R391 *croS* gave 30 – 50 Gal⁺ mutant papillae per colony. Second, we utilized a rifampicin mutagenesis assay in which cells are plated on LB agar plates containing 100 µg ml⁻¹ rifampicin. R391 *croS* strains exhibited a 10-fold increase in rifampicin resistant mutagenesis, as compared to the strains harboring the wild-type R391 (Figure 8). Both of these results demonstrate that the CroS protein, expressed from its native locus within an intact R391, down-regulates *rumAB* and tightly controls mutagenesis in strains carrying the R391 element.

3 | Discussion

3.1 | Unprecedented transcriptional regulation of R391 encoded *rumAB*

Previous studies have shown that chromosomally encoded *E. coli* polV is tightly regulated via a combination of transcriptional, posttranslational and spatial regulation (Goodman et al., 2016). It is therefore likely that polV orthologs are also subject to strict regulation. Indeed, since the mid '90s, when the R391 *rumAB* operon was sequenced, it has been known that *rumAB*-encoded polV_{R391} is regulated by the LexA transcriptional repressor (Kulaeva et al., 1995). Recently, we reported that the *rumAB* operon is also regulated by the λ cI-like transcriptional repressor, SetR_{R391} (Gonzalez et al., 2019). Here, we provide *in vivo* data that is compelling and consistent with CroS_{R391} as acting as a third and potentially the most potent transcriptional regulator of the *rumAB* operon. For example, when expressed in *cis*- or *trans*- with *rumAB*, CroS_{R391} completely inhibits polV_{R391}-dependent mutagenesis (Figs. 3 and 4). The lack of polV_{R391} mutagenesis *in vivo* is attributed to extremely low-level expression of RumA (Figure 4) and RumB (unpublished observations) from its native promoter in the presence of CroS_{R391}. The most reasonable explanation for such a phenotype, is the unhindered access that CroS_{R391} has to the single SetR-CroS binding site in the promoter region of the *rumAB* operon (Figure 1), where it acts as a strong transcriptional repressor of the *rumAB* operon. Interestingly, expression of RumA actually increases when CroS_{R391} and SetR_{R391} are co-expressed (Figs. 4 & 6) implying that SetR_{R391} may at least partially block CroS_{R391} access and binding to the SetR-CroS binding site, thereby preventing it from acting as a potent transcriptional repressor. Indeed, expression of RumA in a wild-type strain after antibiotic-induced SOS induction appears to result from an interplay of all three transcriptional repressors, LexA, SetR_{R391} and CroS_{R391}, such that extremely low levels of polV_{R391} are only present, even after full induction of the SOS response (Figure 6).

polV_{R391} is a potent mutator DNA polymerase when uncoupled from its normal regulatory pathways (Figure 2). Its unprecedented regulation by three separate transcriptional repressors, two of which (LexA and SetR) are cleaved and inactivated after DNA damage, therefore only allows for the very limited expression of the highly error-prone DNA polymerase (Figure 6), before the third (non-cleavable) repressor (CroS), curtails RumAB expression, and provides a mechanism whereby the cell returns to a resting state, with low levels of cellular mutagenesis.

3.2 | Inactivation of *croS*_{R391} increases the potential of enhanced mutagenesis

Deletion of *croS*_{R391} on the intact R391 stably integrated into the *E. coli* genome allowed us to evaluate the effect of the CroS_{R391} protein on repression of the *rumAB*_{R391} operon and mutagenesis from R391 in its native locus. Utilizing both a qualitative *galK2(Oc)* reversion papillation assay (Figure 7), and a quantitative assay rifampicin resistance assay (Figure 8), we found that mutagenesis is significantly increased in MVG114 strains harboring R391 *croS* as compared with strains harboring wild-type R391. These results confirm our assertion that the CroS_{R391} protein is the major R391-encoded negative regulator of the *rumAB*_{R391} operon and indicate that there are likely no additional *rumAB*_{R391} regulators encoded on the full-length R391.

R391 is widely distributed in enterobacteriaceae that are opportunistic pathogens which cause a variety of infections in humans (Song *et al.*, 2013; Bie *et al.*, 2017; Fang *et al.*, 2018; Kong *et al.*, 2020; Slattery *et al.*, 2020). Given that $\text{CroS}_{\text{R391}}$ appears to be the “master regulator” to switch off *rumAB* expression, naturally occurring inactivating mutations in *croS* therefore have the potential of increasing the development and proliferation of $\text{polV}_{\text{R391}}$ -dependent antibiotic resistance in a wide range of pathogenic microorganisms.

4 | EXPERIMENTAL PROCEDURES

4.1 | Bacterial strains and plasmids

Plasmids are listed in Table 1. Bacterial strains are listed in Table 2.

Previously, R391 DNA (formerly known as the IncJ plasmid, R391) was isolated in its unintegrated episomal form in an *E. coli* strain harboring the *recA718* allele (RW96) (Ho *et al.*, 1993). This episomal R391 DNA was partially digested with *EcoRI* and an ~ 21.5 kb fragment was cloned into the low copy number vector pGB2 (Churchward *et al.*, 1984) to generate pRLH421 (Genbank U13633) (Gonzalez *et al.*, 2019). Unfortunately, the pRLH421 plasmid contains a truncation of the $\text{croS}_{\text{R391}}$ gene in the divergent operon with $\text{setR}_{\text{R391}}$ at an internal *EcoRI* within the $\text{croS}_{\text{R391}}$ gene. To reconstruct the $\text{croS}_{\text{R391}}$ gene a fragment, designated “croS complete NarI-PmeI-Bsu36I”, was synthesized (Genscript) that includes from the *NarI* site to the *EcoRI* site of pGB2, the complete $\text{croS}_{\text{R391}}$ open reading frame, the upstream promoter sequences and a *Bsu36I* site replacing the start of the $\text{setR}_{\text{R391}}$ gene. The *croS* complete fragment was subcloned into pRLH421 from the *NarI* (in pGB2) to *PmeI* (in the promoter region) to create an intact $\text{croS}^+_{\text{R391}} \text{setR}^+_{\text{R391}}$ operon (pJM1356). Further, the $\text{croS}_{\text{R391}}$ complete fragment was subcloned into pRLH421 from the *NarI* to *Bsu36I* (in $\text{setR}_{\text{R391}}$) to create a $\text{croS}^+_{\text{R391}} / \text{setR}_{\text{R391}}$ operon within only 222 bp of the 3' end of the $\text{setR}_{\text{R391}}$ gene (pJM1360). Another fragment designated “croS deletion NarI-PmeI-Bsu36I”, was synthesized (Genscript) from the *NarI* site to the first 5 bases of the *EcoRI* site of pGB2, the promoter sequences upstream of the $\text{croS}_{\text{R391}}$ start ATG and a *Bsu36I* site replacing the start of the $\text{setR}_{\text{R391}}$ gene. The *croS* deletion fragment was subcloned into pRLH421 from the *NarI* to *PmeI* to create a $\text{croS}_{\text{R391}} / \text{setR}^+_{\text{R391}}$ operon (pJM1355). Further, the $\text{croS}_{\text{R391}}$ deletion fragment was subcloned into pRLH421 from the *NarI* to *Bsu36I* to create a $\text{croS}_{\text{R391}} / \text{setR}_{\text{R391}}$ operon (pJM1359).

To create plasmids that carry just these four iterations of the $\text{croS}_{\text{R391}} / \text{setR}_{\text{R391}}$ operon, the plasmids pJM1355, pJM1356, pJM1359 and pJM1360 were digested with *ScaI* and *SmaI* and re-ligated, which deletes ~ 20.3 kb of R391, leaving only the $\text{croS}_{\text{R391}} / \text{setR}_{\text{R391}}$ region including about 200 bases downstream of the end of the $\text{setR}_{\text{R391}}$ gene. These plasmids are designated pJM1365 ($\text{croS}_{\text{R391}} / \text{setR}^+_{\text{R391}}$), pJM1366 ($\text{croS}^+_{\text{R391}} / \text{setR}^+_{\text{R391}}$), pJM1367 ($\text{croS}_{\text{R391}} / \text{setR}_{\text{R391}}$) and pJM1368 ($\text{croS}^+_{\text{R391}} / \text{setR}_{\text{R391}}$).

The *rumAB* operon including the *rumAB* promoter region were cloned into the copy control plasmid, pCC1 (Genscript), to generate pJM1378. In addition, the *rumAB* operon fused to the *E. coli* *recA* promoter region was cloned into pCC1 to generate pJM1467 (*recA-prom:rumAB*) (Genscript). These low-copy pCC1Bac plasmids are compatible with the

pGB2-based *croS*_{R391} / *setR*_{R391} plasmids described above, such that the various iterations of the *croS*_{R391} / *setR*_{R391} operon can be co-expressed with the *rumAB* operon.

4.2 | Generation of R391 *croS*.

RW1766/R391 was constructed by inoculating an individual colony of RW1766 and RW120/R391 into 5 mL LB and incubating overnight at 37°C without shaking. The next morning, the culture was streaked on to plates containing Zeocin (25 µg ml⁻¹) and Kanamycin (50 µg ml⁻¹) to select for isolates of RW1766 that had acquired R391 via bacterial conjugation.

The marker-less removal of the *croS* gene from the R391 element of *E. coli* RW1766/R391 was performed according to Zhang *et al.* (Zhang *et al.*, 1998) (see Figure S5). In a first recombination step, a linear *knock out* cassette, generated with primers listed in Table 3, was used to replace the *croS* gene via Red/ET recombination by using plasmid pRed/ET. This resulted in a chloramphenicol-resistant intermediate strain with the genotype *croS*::FRT-Cm^R-FRT (Figure S5). In a second recombination step the selection marker was removed in a FLP recombinase-mediated fashion, leaving a single FRT site at the former *croS* locus (genotype: *croS*::FRT). The intermediate and final clones were analyzed by Sanger-sequencing using primers listed in Table 3 covering the complete modified and adjacent regions.

New strains containing wild-type R391, or R391 *croS*, were made by conjugal transfer of the ICE from RW1766 (Table 2) to the desired recipient strain by selecting on plates containing Streptomycin (100 µg ml⁻¹) and Kanamycin (50 µg ml⁻¹).

4.3 | Qualitative analysis of spontaneous reversion of the *hisG4(Oc)* allele

The *E. coli* strain MVG114 was transformed with various plasmid constructs expressing Cro_{R391}, Set_{R391} and RumAB, either alone, or in various iterations (Table 1). To assay for reversion of the *hisG4(Oc)* allele, three to five isolates of each strain were grown overnight at 37°C in LB medium containing the appropriate antibiotic(s). Five hundred microliters of the cultures were centrifuged, and the pellet resuspended in an equal volume of SM buffer. One hundred microliters of the resuspended pellets were spread on each of five low-histidine minimal plates (Davis and Mingioli minimal agar plates (Davis & Mingioli, 1950) plus glucose (0.4% wt/vol); agar (1.0% wt/vol); proline, threonine, valine, leucine, and isoleucine [all at 100 µg ml⁻¹]; thiamine (0.25 µg ml⁻¹); and histidine (1 µg ml⁻¹)]. After incubating the plates for four days at 37°C, the His⁺ mutant colonies were counted and averaged between the independent cultures and standard error of the mean (SEM) calculated.

4.4 | *galK2(Oc)* reversion papillation assay

The *galK2(oc)* papillation is a visual reversion mutagenesis assay that was previously used to identify genes from R-plasmids that encode orthologs of the *E. coli umuDC* genes including *rumAB* from R391 (Ho *et al.*, 1993). Briefly, ~ 50– 75 *E. coli* cells harboring the *galK2(Oc)* allele are plated onto MacConkey-galactose agar media and grown for 8 days at 37°C. The number of small orange-red Gal⁺ papillae that grow up within a bacterial

colony are noted from multiple colonies. Comparison of the number of papillae allows the assessment of the level of mutagenesis in the MVG114 strains harboring R391 versus MVG114 harboring R391 *croS*.

4.5 | Rifampicin mutagenesis assay

Selection for rifampicin resistance is another generally used mutagenesis assay. Base-pair substitution mutations arising within the central 202 bp of the *spoB* gene can give rise to resistance to the rifampicin antibiotic. Five milliliter cultures of MVG114/R391 and MVG114/R391 *croS* were started, in triplicate, from an initial inoculum containing ~ 1000 viable cells and grown for 24 h at 37°C. One hundred microliters of these cultures were spread on five LB agar plates containing 100 µg ml⁻¹ rifampicin. In addition, these cultures were serially diluted and appropriate volumes were plated to LB agar plates to determine viable cell counts. Subsequently, frequencies of rifampicin mutations arising within the cultures was calculated.

4.6 | Western blot analysis of CroS_{R391}, RumA_{R391} and RecA proteins

E. coli cultures were grown in Luria-Bertani media at 37°C until exponential phase (OD₆₀₀ ~0.5). For the experiments shown in Figure 6, Ciprofloxacin (30 ng ml⁻¹) was added to the culture and cells harvested by centrifugation at subsequent time points (as indicated in Figure 6). For all other experiments, undamaged cells were harvested at an OD₆₀₀ ~0.5. The cell pellet was resuspended in NuPage LDS sample buffer (Novex) and freeze-thawed to produce whole cell extracts. Cell extracts were electrophoresed on NuPage 4–12% Bis-Tris gels (Novex). Proteins were transferred to an Invitrolon PVDF membrane (Novex) which was probed with appropriate dilutions of affinity purified rabbit anti-CroS_{R391}, anti-RumA_{R391} or anti-*E. coli* RecA antibodies and subsequently probed with an appropriate dilution of Goat Anti-Rabbit IgG (H+L)-AP Conjugate (Bio-Rad). Using the CDP-Star chemiluminescent assay (Tropix), the CroS_{R391}, RumA_{R391}/A'_{R391} or RecA proteins were visualized on Carestream Biomax XAR film after various exposure times. Digital images were also captured using an Alpha Innotech FluorChem HD2. These images were then imported as .tif files into LI-COR Biosciences Image Studio Lite software, where band density was quantified using the Data Analysis tool. Relative protein levels for bands of interest were calculated by normalizing band density to that of non-specific bands within each lane, then expressed relative to a cross-reacting reference band.

4.7 | Overexpression and purification of CroS.

The gene encoding R391 *croS* was codon optimized for expression in *E. coli* and chemically synthesized (Genscript) as a 309 bp *NdeI-PstI* fragment and cloned into pUC57 (Genscript). The *NdeI-PstI* fragment was subsequently sub-cloned into the same sites of pCF2. pCF2 is a medium copy plasmid that expresses IPTG-inducible glutathione-*S* transferase (GST). The construct also contains a PreScission (GE Healthcare) protease site immediately downstream of the GST protein and upstream of the unique *NdeI* site. When the target gene is cloned into the *NdeI* site of pCF2, a GST-fusion protein is generated with a PreScission site immediately upstream of the target protein. CroS was initially purified as a GST-CroS fusion protein as a custom service by scientists at Eurofins, as previously described (Poulin-Laprade & Burrus,

2015) and the GST-affinity tag subsequently removed after PreScission protease treatment (Eurofins).

4.8 | CroS Antibodies

Polyclonal antibodies to the purified CroS protein were raised in rabbits as a custom service (Covance) and affinity purified. These antibodies are highly specific with very few cross-reacting bands in western blots of *E. coli* extracts lacking CroS.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

This work was funded in part by the NICHD/NIH Intramural Research Program to RW, and from the Southwestern University Faculty- Student Collaborative Projects Fund and the Lizanell and Colbert Coldwell Foundation to MG. We thank Nicholas Ashton, LGI/NIH, for assistance with generating the figures shown herein, as well as quantifying the levels of RumA and RumA' reported in Figs 4, 5, 6 and S5.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Abbreviations:

TLS	Translesion DNA synthesis
ICE	Integrating Conjugative Element
polV	DNA polymerase V
RecA*	Activated RecA-nucleoprotein filament

REFERENCES

- Bagg A, Kenyon CJ & Walker GC, (1981) Inducibility of a gene product required for UV and chemical mutagenesis in *Escherichia coli*. Proc Natl Acad Sci U S A 78: 5749–5753. [PubMed: 7029544]
- Beaber JW, Hochhut B & Waldor MK, (2004) SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature 427: 72–74. [PubMed: 14688795]
- Bhattarai K, Bastola R & Baral B, (2020) Antibiotic drug discovery: Challenges and perspectives in the light of emerging antibiotic resistance. Adv Genet 105: 229–292. [PubMed: 32560788]
- Bie L, Wu H, Wang XH, Wang M & Xu H, (2017) Identification and characterization of new members of the SXT/R391 family of integrative and conjugative elements (ICEs) in *Proteus mirabilis*. Int J Antimicrob Agents 50: 242–246. [PubMed: 28602701]
- Boltner D, MacMahon C, Pembroke JT, Strike P & Osborn AM, (2002) R391: a conjugative integrating mosaic comprised of phage, plasmid, and transposon elements. J Bacteriol 184: 5158–5169. [PubMed: 12193633]
- Burckhardt SE, Woodgate R, Scheuermann RH & Echols H, (1988) UmuD mutagenesis protein of *Escherichia coli*: overproduction, purification and cleavage by RecA. Proc Natl Acad Sci U S A 85: 1811–1815. [PubMed: 3279417]

- Churchward G, Belin D & Nagamine Y, (1984) A pSC101-derived plasmid which shows no sequence homology to other commonly used cloning vectors. *Gene* 31: 165–171. [PubMed: 6098521]
- Cirz RT, Gingles N & Romesberg FE, (2006a) Side effects may include evolution. *Nat Med* 12: 890–891. [PubMed: 16892033]
- Cirz RT, Jones MB, Gingles NA, Minogue TD, Jarrahi B, Peterson SN & Romesberg FE, (2007) Complete and SOS-mediated response of *Staphylococcus aureus* to the antibiotic ciprofloxacin. *J Bacteriol* 189: 531–539. [PubMed: 17085555]
- Cirz RT, O'Neill BM, Hammond JA, Head SR & Romesberg FE, (2006b) Defining the *Pseudomonas aeruginosa* SOS response and its role in the global response to the antibiotic ciprofloxacin. *J Bacteriol* 188: 7101–7110. [PubMed: 17015649]
- Cirz RT & Romesberg FE, (2006) Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. *Antimicrob Agents Chemother* 50: 220–225. [PubMed: 16377689]
- Davis BD & Mingioli ES, (1950) Mutants of *Escherichia coli* requiring methionine or vitamin B12. *J Bacteriol* 60: 17–28. [PubMed: 15436457]
- Fang Y, Wang Y, Li Z, Liu Z, Li X, Diao B, Kan B & Wang D, (2018) Distribution and genetic characteristics of SXT/R391 Integrative Conjugative Elements in *Shewanella* spp. from China. *Front Microbiol* 9: 920. [PubMed: 29867831]
- Fernández de Henestrosa AR, Ogi T, Aoyagi S, Chafin D, Hayes JJ, Ohmori H & Woodgate R, (2000) Identification of additional genes belonging to the LexA-regulon in *Escherichia coli*. *Mol Microbiol* 35: 1560–1572. [PubMed: 10760155]
- Fijalkowska IJ, Dunn RL & Schaaper RM, (1997) Genetic requirements and mutational specificity of the *Escherichia coli* SOS mutator activity. *J Bacteriol* 179: 7435–7445. [PubMed: 9393709]
- Frank EG, Ennis DG, Gonzalez M, Levine AS & Woodgate R, (1996) Regulation of SOS mutagenesis by proteolysis. *Proc Natl Acad Sci U S A* 93: 10291–10296. [PubMed: 8816793]
- Gonzalez M, Frank EG, Levine AS & Woodgate R, (1998) Lon-mediated proteolysis of the *Escherichia coli* UmuD mutagenesis protein: *in vitro* degradation and identification of residues required for proteolysis. *Genes Dev* 12: 3889–3899. [PubMed: 9869642]
- Gonzalez M, Huston D, McLenigan MP, McDonald JP, Garcia AM, Borden KS & Woodgate R, (2019) SetR_{ICE391}, a negative transcriptional regulator of the integrating conjugative element 391 mutagenic response. *DNA Repair* 73: 99–109. [PubMed: 30581075]
- Gonzalez M, Rasulova F, Maurizi MR & Woodgate R, (2000) Subunit-specific degradation of the UmuD/D' heterodimer by the ClpXP protease: The role of trans recognition in UmuD' stability. *EMBO J* 19: 5251–5258. [PubMed: 11013227]
- Goodman MF, McDonald JP, Jaszczur MM & Woodgate R, (2016) Insights into the complex levels of regulation imposed on *Escherichia coli* DNA polymerase V. *DNA Repair* 44: 42–50. [PubMed: 27236212]
- Ho C, Kulaeva OI, Levine AS & Woodgate R, (1993) A rapid method for cloning mutagenic DNA repair genes: isolation of *umu*-complementing genes from multidrug resistance plasmids R391, R446b, and R471a. *J Bacteriol* 175: 5411–5419. [PubMed: 8366028]
- Hochhut B, Beaber JW, Woodgate R & Waldor MK, (2001) Formation of chromosomal tandem arrays of the SXT Element and R391, two conjugative chromosomally integrating elements that share an attachment site. *J Bacteriol* 183: 1124–1132. [PubMed: 11157923]
- Jiang Q, Karata K, Woodgate R, Cox MM & Goodman MF, (2009) The active form of DNA polymerase V is UmuD'₂C-RecA-ATP. *Nature* 460: 359–363. [PubMed: 19606142]
- Johnson A, Meyer BJ & Ptashne M, (1978) Mechanism of action of the cro protein of bacteriophage λ. *Proc Natl Acad Sci U S A* 75: 1783–1787. [PubMed: 273909]
- Kong LH, Xiang R, Wang YL, Wu SK, Lei CW, Kang ZZ, Chen YP, Ye XL, Lai Y & Wang HN, (2020) Integration of the *bla*_{NDM-1} carbapenemase gene into a novel SXT/R391 integrative and conjugative element in *Proteus vulgaris*. *J Antimicrob Chemother* 75: 1439–1442. [PubMed: 32155266]
- Kulaeva OI, Wootton JC, Levine AS & Woodgate R, (1995) Characterization of the *umu*-complementing operon from R391. *J Bacteriol* 177: 2737–2743. [PubMed: 7751283]

- McCall JO, Witkin EM, Kogoma T & Roegner-Maniscalco V, (1987) Constitutive expression of the SOS response in *recA718* mutants of *Escherichia coli* requires amplification of RecA718 protein. *J Bacteriol* 169: 728–734. [PubMed: 3542969]
- McDonald JP, Vaisman A, Kuban W, Goodman MF & Woodgate R, (2012) Mechanisms employed by *Escherichia coli* to prevent ribonucleotide incorporation into genomic DNA by pol V. *PLoS Genet* 8: e1003030. [PubMed: 23144626]
- McLenigan MP, Kulaeva OI, Ennis DG, Levine AS & Woodgate R, (1999) The bacteriophage P1 HumD protein is a functional homolog of the prokaryotic UmuD'-like proteins and facilitates SOS mutagenesis in *Escherichia coli*. *J Bacteriol* 181: 7005–7013. [PubMed: 10559166]
- Mead S, Vaisman A, Valjavec-Gratian M, Karata K, Vandewiele D & Woodgate R, (2007) Characterization of polV_{R391}: a Y-family polymerase encoded by *rumA'B* from the IncJ conjugative transposon, R391. *Mol Microbiol* 63: 797–810. [PubMed: 17302804]
- Nohmi T, Battista JR, Dodson LA & Walker GC, (1988) RecA-mediated cleavage activates UmuD for mutagenesis: mechanistic relationship between transcriptional derepression and posttranslational activation. *Proc Natl Acad Sci U S A* 85: 1816–1820. [PubMed: 3279418]
- Pinney RJ, (1980) Distribution among incompatibility groups of plasmids that confer UV mutability and UV resistance. *Mutat Res* 72: 155–159. [PubMed: 6777687]
- Poulin-Laprade D & Burrus V, (2015) A λ Cro-Like repressor Is essential for the induction of conjugative transfer of SXT/R391 elements in response to DNA damage. *J Bacteriol* 197: 3822–3833. [PubMed: 26438816]
- Poulin-Laprade D, Matteau D, Jacques PE, Rodrigue S & Burrus V, (2015) Transfer activation of SXT/R391 integrative and conjugative elements: unraveling the SetCD regulon. *Nucleic Acids Res* 43: 2045–2056. [PubMed: 25662215]
- Robinson A, McDonald JP, Caldas VE, Patel M, Wood EA, Punter CM, Ghodke H, Cox MM, Woodgate R, Goodman MF & van Oijen AM, (2015) Regulation of mutagenic DNA polymerase V: activation in space and time. *PLoS Genet* 11: e1005482. [PubMed: 26317348]
- Shinagawa H, Iwasaki H, Kato T & Nakata A, (1988) RecA protein-dependent cleavage of UmuD protein and SOS mutagenesis. *Proc Natl Acad Sci U S A* 85: 1806–1810. [PubMed: 3126496]
- Simmons LA, Foti JJ, Cohen SE & Walker GC, (2008) The SOS Regulatory Network. *EcoSal Plus* 2008. doi:10.1128/ecosalplus.5.4.3
- Slattery S, Tony Pembroke J, Murnane JG & Ryan MP, (2020) Isolation, nucleotide sequencing and genomic comparison of a novel SXT/R391 ICE mobile genetic element isolated from a municipal wastewater environment. *Sci Rep* 10: 8716. [PubMed: 32457296]
- Song Y, Yu P, Li B, Pan Y, Zhang X, Cong J, Zhao Y, Wang H & Chen L, (2013) The mosaic accessory gene structures of the SXT/R391-like integrative and conjugative elements derived from *Vibrio* spp. isolated from aquatic products and environment in the Yangtze River Estuary, China. *BMC Microbiol* 13: 214. [PubMed: 24074349]
- Svenningsen SL, Costantino N, Court DL & Adhya S, (2005) On the role of Cro in λ prophage induction. *Proc Natl Acad Sci U S A* 102: 4465–4469. [PubMed: 15728734]
- Sweasy JB, Witkin EM, Sinha N & Roegner-Maniscalco V, (1990) RecA protein of *Escherichia coli* has a third essential role in SOS mutator activity. *J Bacteriol* 172: 3030–3036. [PubMed: 2188949]
- Szekeres ESJ, Woodgate R & Lawrence CW, (1996) Substitution of *mucAB* or *rumAB* for *umuDC* alters the relative frequencies of the two classes of mutations induced by a site-specific T-T cyclobutane dimer and the efficiency of translesion DNA synthesis. *J Bacteriol* 178: 2559–2563. [PubMed: 8626322]
- Takeda Y, Folkmanis A & Echols H, (1977) Cro regulatory protein specified by bacteriophage λ . Structure, DNA-binding, and repression of RNA synthesis. *J Biol Chem* 252: 6177–6183. [PubMed: 330523]
- Tang M, Shen X, Frank EG, O'Donnell M, Woodgate R & Goodman MF, (1999) UmuD'₂C is an error-prone DNA polymerase, *Escherichia coli*, DNA pol V. *Proc Natl Acad Sci U S A* 96: 8919–8924. [PubMed: 10430871]
- Upton C & Pinney RJ, (1983) Expression of eight unrelated Muc⁺ plasmids in eleven DNA repair-deficient *E. coli* strains. *Mutat Res* 112: 261–273. [PubMed: 6314133]

- Wang J, Sarov M, Rientjes J, Fu J, Hollak H, Kranz H, Xie W, Stewart AF & Zhang Y, (2006) An improved recombineering approach by adding RecA to λ Red recombination. *Mol Biotechnol* 32: 43–53. [PubMed: 16382181]
- Wendlandt S, Shen J, Kadlec K, Wang Y, Li B, Zhang WJ, Fessler AT, Wu C & Schwarz S, (2015) Multidrug resistance genes in *staphylococci* from animals that confer resistance to critically and highly important antimicrobial agents in human medicine. *Trends Microbiol* 23: 44–54. [PubMed: 25455417]
- Woodgate R, Rajagopalan M, Lu C & Echols H, (1989) UmuC mutagenesis protein of *Escherichia coli*: purification and interaction with UmuD and UmuD'. *Proc Natl Acad Sci U S A* 86: 7301–7305. [PubMed: 2552436]
- Zhang Y, Buchholz F, Muyrers JP & Stewart AF, (1998) A new logic for DNA engineering using recombination in *Escherichia coli*. *Nat Genet* 20: 123–128. [PubMed: 9771703]

**FIGURE 1.**

Cartoon of the *rumAB* promoter region. A single SetR/CroS binding site is shown in blue color. This site partially overlaps with the -35 promoter element, shown in gold. A LexA binding site is shown in green, which partially overlaps with the -10 promoter element (also shown in gold). The ribosome binding site (RBS) is shown in purple and the first two codons of RumA are shown in red.




FIGURE 2. Spontaneous mutagenesis promoted by R391, or pRW290, in different genetic backgrounds. Cells were plated on minimal low histidine agar plates as described in section 4.3; *Qualitative analysis of spontaneous reversion of the hisG4(Oc) allele*. His⁺ revertants appear as creamy white colonies against the dark background behind the agar plate. As observed, the 88.5kb R391 promotes low levels of spontaneous mutagenesis in all genetic backgrounds. This is in contrast to pRW290, which only expresses the *rumAB*_{R391} operon from a low-copy-number vector. Although the *rumAB* operon is subject to transcriptional

regulation by the LexA repressor there is little difference in mutagenesis between *lexA*⁺ (RW120) and *lexA51*(Def) (RW546) strains. Mutagenesis increases significantly when RecA is partially activated for co-protease functions (*recA718*; MVG114), or fully activated for co-protease functions (*recA730*; RW578).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





FIGURE 3.

RumAB_{R391}-dependent mutagenesis is regulated by *croS*_{R391}.

The histidine reversion assay was performed on the *E. coli* strain MVG114 or MVG114 strains transformed with pRLH421 or various *croS*_{R391} or *setR*_{R391} wild-type or deletion combinations. (wt/ C) represents MVG114 transformed with the plasmid pRLH421 which contains ~ 21.5 kb of R391 and harbors a C-terminal deletion of the *croS*_{R391} gene. MVG114 was transformed with plasmids pJM1355, pJM1356, pJM1359 and pJM1360 and the *croS*_{R391} or *setR*_{R391} genotypes are indicated. Error bars indicate standard error of the mean (SEM).

**FIGURE 4.**

CroS_{R391} *trans*-regulation of RumAB_{R391}-dependent mutagenesis.

(a). Spontaneous Histidine reversion mutagenesis assays utilizing MVG114 strains harboring pJM1378 alone (–/–), a pCC1-derivative (copy-control plasmid) carrying the *rumAB*_{R391} operon, were transformed with low-copy pGB2-derivatives (pJM1365, pJM1366, pJM1367 and pJM1368) carrying various iterations of the *croS*_{R391} / *setR*_{R391} operon (Table 1). The genotypes of *croS*_{R391} or *setR*_{R391}, either wild-type, or deleted, are indicated. (b). Western blot analysis using an anti-CroS antibody indicating that only strains


harboring a plasmid with a wild-type *croS*_{R391} gene express any CroS protein. (c). Western blot using an anti-RumA antibody indicating that strains that express the CroS protein have significantly reduced levels of the RumA protein. However, strains that express only SetR show no reduction in the level of RumA protein. Numbers reported for the levels of RumA and RumA' are relative to RumA in track 1.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript

**FIGURE 5.**

CroS_{R391} regulation of RumA_{R391}-dependent mutagenesis is dependent on the *rumAB*_{R391} promoter region.

(a). Spontaneous Histidine reversion mutagenesis assays utilizing MVG114 strains harboring pJM1467 (–/–), a pCC1-derivative carrying the *rumAB*_{R391} operon under the control of the *recA* promoter, were transformed with low-copy pGB2-derivatives (pJM1365, pJM1366, pJM1367 and pJM1368) carrying various iterations of the *croS*_{R391}-*setR*_{R391} operon (Table 1). The genotypes of *croS*_{R391} or *setR*_{R391}, either wild-type, or deleted, are indicated. The histogram illustrates the mean colony count for each indicated strain (n = 5). Error bars represent the standard error of the mean (SEM). An unpaired two-tailed *t* test was used to compare the mean colony counts for the *setR* *croS* and *setR* *croS*⁺ strains. * = p < 0.05. **(b).** Western blot using an anti-RumA antibody indicating that the level of RumA expressed from the *E. coli* *recA* promoter do not change appreciably in the presence, or absence, of SetR or CroS. Numbers reported for the expression levels of RumA and RumA' are relative to RumA in the left-hand lane.

**FIGURE 6.**

Expression of RecA, RumA and RumA' in wild-type *recA*⁺ *lexA*⁺ cells after exposure to the SOS-inducing antibiotic, Ciprofloxacin.

Western blot analysis was performed on whole-cell protein extracts from RW520 (*recA*⁺ *lexA*⁺) harboring pRLH421 derivatives (pJM1355, pJM1356, pJM1359 or pJM1360), with various *croS*_{R391} or *setR*_{R391} wild-type, or deletion combinations as indicated. To induce the SOS response, cells were treated with 30 ng ml⁻¹ Ciprofloxacin for various times, as indicated in the figure. Levels of RecA and RumA/ RumA' were detected using affinity purified polyclonal rabbit antibodies to RecA and RumA proteins. The number reported for the level of RumA or RumA' are relative to a cross-reacting band in the same track.





FIGURE 7. *galK2(Oc)* reversion papillation assay of R391, or R391 Δ *croS* strains. R391, or R391 Δ *croS* were moved into MVG114 by conjugal transfer. Cells were plated onto MacConkey-galactose agar media and grown for 8 days at 37°C. Pictures of representative colonies from each strain were taken showing the appearance of Gal⁺ papillae indicating the level of mutagenesis occurring within the colonies. The MVG114/R391 Δ *croS* colonies contain approximately 10 –50 times the number of revertant papillae, when compared to the MVG114/R391 colonies.

**FIGURE 8.**

Rifampicin mutagenesis assay of R391 and R391 *croS* strains.

MVG114, MVG114/R391 and MVG114/R391 *croS* cultures were started from with approximately 1000 cells, or less, and grown over night to stationary phase. Cells were plated onto LB agar plates containing rifampicin to select for rifampicin resistant mutants. Appropriate dilutions were plated to LB agar plates to determine viable counts and the frequency of mutagenesis to rifampicin resistance was calculated. Error bars represent the standard error of the mean (SEM). The MVG114/R391 *croS* strain exhibits an ~10-fold higher frequency of mutagenesis to rifampicin resistance than the MVG114/R391 strain.

Table 1.

Plasmids used in this study

Plasmid	Relevant Characteristics	Source or reference
R391	Integrated into <i>prfC</i>	(Ho et al., 1993)
R391 <i>croS</i>	Integrated into <i>prfC</i> and with a deletion of <i>croS</i> _{R391}	This study
pRW290	Low copy number, Spc ^R , ~2 kb fragment of R391 expressing <i>rumAB</i>	(Szekeres et al., 1996)
pRLH421	Low-copy-number, Spc ^R , ~21.5 kb fragment of R391	Genbank:U13633 (Gonzalez et al., 2019)
pJM1355	Low-copy-number, Spc ^R , ~21.5 kb fragment of R391 with <i>croS</i> _{R391} <i>setR</i> ⁺ _{R391}	This study
pJM1356	Low-copy-number, Spc ^R , ~21.5 kb fragment of R391 with <i>croS</i> ⁺ _{R391} <i>setR</i> ⁺ _{R391}	This study
pJM1359	Low-copy-number, Spc ^R , ~21.5 kb fragment of R391 with <i>croS</i> _{R391} <i>setR</i> _{R391}	This study
pJM1360	Low-copy-number, Spc ^R , ~21.5 kb fragment of R391 with <i>croS</i> ⁺ _{R391} <i>setR</i> _{R391}	This study
pJM1365	Low-copy-number, Spc ^R , with <i>croS</i> _{R391} <i>setR</i> ⁺ _{R391}	This study
pJM1366	Low-copy-number, Spc ^R , with <i>croS</i> ⁺ _{R391} <i>setR</i> ⁺ _{R391}	This study
pJM1367	Low-copy-number, Spc ^R , with <i>croS</i> _{R391} <i>setR</i> _{R391}	This study
pJM1368	Low-copy-number, Spc ^R , with <i>croS</i> ⁺ _{R391} <i>setR</i> _{R391}	This study
pCC1Bac TM	Single-copy-number, Cm ^R	Genscript
pJM1378	pCC1-based, Cm ^R , with <i>rumAB</i> _{R391}	This study
pJM1467	pCC1-based, Cm ^R , with <i>recA-promoter::rumAB</i> _{R391}	This study
pRed/ET	Plasmid encoding the <i>red</i> gene cluster (<i>redγβα</i>) and <i>recA</i> Tet ^R	(Wang et al., 2006)
pFLPe	Plasmid encoding the enhanced FLP recombinase, Amp ^R	Gen-H

Table 2.*E. coli* strains used in this study

Strain	Relevant Genotype	Source or reference
RW120 ^a	<i>umuDC595::cat hisG4(Oc) galK2(Oc)</i>	(Ho et al., 1993)
RW546 ^a	<i>umuDC595::cat lexA51(Def) hisG4(Oc) galK2(Oc)</i>	(Fernández de Henestrosa et al., 2000)
RW578 ^a	<i>umuDC595::cat lexA51(Def) recA730 hisG4(Oc) galK2(Oc)</i>	(Mead et al., 2007)
RW520 ^a	<i>umuDC596::ermGT hisG4(Oc) galK2(Oc)</i>	LGI stocks
RW584 ^a	<i>umuDC596::ermGT lexA51(Def) recA730 hisG4(Oc) galK2(Oc)</i>	(McDonald et al., 2012)
MVG114 ^a	<i>umuDC596::ermGT lexA51(Def) recA718 hisG4(Oc) galK2(Oc)</i>	(Gonzalez et al., 2019)
MVG114 ^a	R391	This study
RW1766 ^b	<i>dinB61::ble</i>	This study
MVG114 ^a	R391 <i>croS</i>	This study

^a: Full genotype: *thr-1 araD139 (gpt-proA)62 lacY1 tsx-33 glnV44 rpsL31 xyl-5 mtl-1 argE3 thi-1 sulA211*

^b: *dinB61::ble* derivative of MG1655 (F⁻ λ -*rph-1*)

Table 3.

Oligonucleotides used in this study

Name	Sequence	Source
p1 ^a	CTCGCTTTTGTGTTTACGTAAAATGCTGACCATTATTTGCCCTTAATCCTAAATTAACCCTCACTAAAGGGCGG	BioSpring
p2 ^a	CAGTTTAAACTGTAACATTCAATCTTGTAACAGTTATTATTGTAACAGGAGACGGTTAGCACGGAGTTCATTAGGGCTC	Biospring
cp01 ^b	GCGATGCCATACCAATGAAGTCG	BioSpring
cp02 ^b	CAACGTAACCAATCGGCAGTCG	BioSpring
cp03 ^b	CCAGTGACTTCACGCCACTCC	BioSpring
cp04 ^b	CAGGATCAACAACGATCACTGCC	BioSpring

^a: Used in the generation of linear *knock out* cassette.

^b: Used in the amplification of the modified region and subsequent DNA sequencing